title: Is it necessary to conduct trials with trimethoprim-sulphamethoxazole amongst HIV-infected individuals in Africa?
authors.forename: B
authors.initials: B
authors.lastname: Samb
authors.forename: M
authors.initials: M
authors.lastname: Badiane
authors.forename: S
authors.initials: S
authors.lastname: Kony
authors.forename: B
authors.initials: B
authors.lastname: Larouzé
authors.forename: M A
authors.initials: MA
authors.lastname: Faye
authors.forename: P S
authors.initials: PS
authors.lastname: Sow
authors.forename: S
authors.initials: S
authors.lastname: Badiane
authors.forename: A
authors.initials: A
authors.lastname: Metro
authors.forename: D
authors.initials: D
authors.lastname: Costagliola
authors.forename: I
authors.initials: I
authors.lastname: Ndoye
authors.forename: E
authors.initials: E
authors.lastname: Delaporte
authors.forename: A M
authors.initials: AM
authors.lastname: Coll-Seck
authors.forename: J P
authors.initials: JP
authors.lastname: Coulaud
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000517:prevention & control*; D000890:Anti-Infective Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D006801:Humans; D011020:Pneumonia, Pneumocystis / Q000517:prevention & control; D012675:Senegal; D014123:Toxoplasmosis / Q000517:prevention & control; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000890:Anti-Infective Agents; D015662:Trimethoprim, Sulfamethoxazole Drug Combination